Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

Table 5 CDR-SB scores at baseline and the 24th week

Variables	KGT group (n = 16)			Placebo group (n = 14)			Between-group comparison
Variables	Baseline	24th week	p-value^†	Baseline	24th week	p-value^†	p-value^*
CDR-SB score	1.53 (0.64) 1.50 (1.00–2.00)	1.13 (0.62) 1.00 (0.50–1.50)	0.010	1.61 (0.88) 1.50 (0.88–2.50)	1.75 (0.94) 1.75 (0.88–2.50)	0.453	0.045

CDR-SB, Clinical Dementia Rating-Sum of Boxes; KGT, Kami-guibi-tang
Values are presented as means (standard deviations) and medians (Q1–Q3)
^†p-value for the intergroup comparison using Wilcoxon’s signed rank test
^*p-value for the between-group comparison of the 24th-week scores using the Mann-Whitney U test

ISSN: 2662-7671